Two Cases of Segmental Multiple Glomangiomas in a Family: Type 1 or Type 2 Segmental Manifestation?Peña-Penabad C.a · García-Silva J.a · del Pozo J.a · Yebra-Pimentel M.T.b · Fonseca E.a · Cuevas J.c · Contreras F.d
Departments of aDermatology and bPathology, Hospital Juan Canalejo, La Coruña, cDepartment of Pathology, Hospital General, Guadalajara, and dDepartment of Pathology, Hospital La Paz, Madrid, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Several autosomal dominant skin diseases may manifest cutaneous mosaicism. Two types of segmental arrangement can be distinguished: type 1 is characterized by segmental lesions with similar severity to that observed in the diffuse phenotype, the remaining skin being normal; type 2 is characterized by segmental lesions showing a major degree of severity and milder lesions diffusely arranged. Multiple glomus tumours have recently been included in the group of genodermatoses showing type 2 segmental involvement. A family with 2 cases of multiple glomangiomas arranged in a segmental fashion is reported. A 12-year-old girl presented multiple nodular glomangiomas on her right buttock and thigh, in a band-like distribution. A sister of her paternal grandfather showed plaque-like multiple glomangiomas on her left thigh and various glomangiomas on her right buttock and arm. No other family members were known to be affected. Two new cases of familial segmental multiple glomangiomas are reported, with the particularity that one of these exhibited type 2 segmental manifestation and the other type 1 from a clinical point of view.
© 2000 S. Karger AG, Basel
- Parsons ME, Russo G, Fucich L, Millikan LE, Kim R: Multiple glomus tumors. Int J Dermatol 1997;36:894–900.
- Happle R, König A: Type 2 segmental manifestation of multiple glomus tumors: A review and reclassification of 5 case reports. Dermatology 1999;198:270–272.
- Pepper MC, Laubenheimer R, Cripps DJ: Multiple glomus tumors. J Cutan Pathol 1977;4:244–257.
- Rudolph R: Familial multiple glomangiomas. Ann Plast Surg 1993;30:183–185.
Lawlor KB, Helm TH, Narurkar V, Vidimos A: Stump the experts – Multiple glomus tumors. J Dermatol Surg Oncol 1994;20:572, 629–630.
Mora Morillas I, Sánchez Yus E, Sánchez Lozano JL, Abad Asensio E, García Pérez A: Glomangiomatosis múltiple diseminada. Actas Dermosifiliogr 1987;78:239–243.
- Yoon TY, Lee HT, Chang SH: Giant congenital multiple patch-like glomus tumors. J Am Acad Dermatol 1999;40:826–828.
- Landthaler M, Braun-Falco O, Eckert F, Stoltz W, Dorn M, Wolff HH: Congenital multiple plaquelike glomus tumors. Arch Dermatol 1990;126:1203–1207.
- Yang JS, Ko JW, Suh KS, Kim ST: Congenital multiple plaque-like glomangiomyoma. Am J Dermatopathol 1999;21:454–457.
- Happle R: A rule concerning the segmental manifestation of autosomal dominant skin disorders: Review of clinical examples providing evidence for dichotomous types of severity. Arch Dermatol 1997;133:1505–1509.
- Happle R: Loss of heterozygosity in human skin. J Am Acad Dermatol 1999;41:143–161.
- Happle R: Segmental forms of autosomal dominant skin disorders: Different types of severity reflect different states of zygosity. Am J Med Genet 1996;66:241–242
- Merino Monje E, Guerra Tapia A, Moreno Izquierdo R, Barrio Fuertes A: Multiple glomus tumors: Regional and disseminated form in the same patient – Report of a case (in Spanish). Actas Dermosifiliogr 1978;69:393–398.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.